Presgrave P, Woods R L, Tattersall M H, Coates A S, Levi J A, Fox R M, Hedley D
Department of Clinical Oncology, Royal North Shore Hospital, St. Leonards, Sydney, New South Wales, Australia.
Cancer Treat Rep. 1987 Nov;71(11):1087-8.
Thirty-six adult patients with measurable advanced soft tissue sarcoma were treated with a combination of doxorubicin (70 mg/m2) and methotrexate (50 mg/m2) iv every 21 days. Partial remission was seen in ten of 33 evaluable patients (30%). Median duration of remission was 23 weeks, and median survival was 42 weeks. Bone marrow toxicity was the main toxic effect; 23% of the patients had a nadir leukocyte count less than 2.0 X 10(9)/L during therapy. These results do not suggest any therapeutic advantage in adding methotrexate to doxorubicin in this context.
36例患有可测量的晚期软组织肉瘤的成年患者接受了阿霉素（70mg/m²）和甲氨蝶呤（50mg/m²）联合静脉注射治疗，每21天一次。33例可评估患者中有10例（30%）出现部分缓解。缓解的中位持续时间为23周，中位生存期为42周。骨髓毒性是主要的毒性作用；23%的患者在治疗期间白细胞计数最低点低于2.0×10⁹/L。这些结果并不表明在此情况下将甲氨蝶呤添加到阿霉素治疗中有任何治疗优势。
